CA-CEPTON-TECHNOLOGIES
11.10.2021 15:02:06 CEST | Business Wire | Press release
Cepton Technologies, Inc., an innovative provider of smart lidar solutions , announced today its membership in the Qualcomm® Smart Cities Accelerator Program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005191/en/
The Qualcomm Smart Cities Accelerator Program brings technologies and companies together to collaborate, innovate, and accelerate the rollout of smart cities and smart connected spaces globally. Cepton believes its presence in this ecosystem aligns with Qualcomm Technologies, Inc.’s vision of bringing efficient, safe, and advanced technology to fast-growing urban environments. With its membership, Cepton aims to advance the use of lidar-based solutions with ecosystem members of the Qualcomm Smart Cities Accelerator Program across smart cities and smart connected spaces.
Through the Qualcomm® IoT Services Suite, Cepton and one of its key partners in smart spaces, The Indoor Lab, plan to collaborate with Qualcomm Technologies in offering Smart Venues as a Service , utilizing a lidar-based crowd analytics system which adheres to the privacy concerns and optimizes the utilization of spaces.
With its high-accuracy, 3D perception capabilities and 24/7 availability , lidar can enable a wide range of applications to help build safer, smarter, and better-connected environments. Thanks to their anonymized data, lidars maximize protection of people’s privacy as they collect useful information to help drive intelligent decisions in smart cities and smart spaces. Cepton has been working with global partners to enable the transformation of transportation infrastructure, public venues and large commercial facilities using smart lidar solutions. For example, Cepton’s partnership with The Indoor Lab deployed a lidar-based crowd analytics solution as a pilot project at an Orlando International Airport terminal in 2020 to offer anonymous foot fall tracking, helping maintenance crews in targeted cleaning and travelers in avoiding crowded areas.
“We are proud to join Qualcomm Technologies’ network of technology innovators through the Qualcomm Smart Cities Accelerator Program as we work to help advance the future of smart infrastructure with our lidar technologies,” said Dr. Jun Pei, CEO of Cepton. “To date, our technology has been successfully used to enable real-time traffic and pedestrian monitoring at road and rail intersections , free-flow electronic tolling systems , critical infrastructure security , and crowd analytics . By joining the Qualcomm Smart Cities Accelerator Program ecosystem, we look forward to making our technologies more accessible on a global scale.”
“Our partnership with Cepton has been invaluable to establish The Indoor Lab as a market leader for lidar-based analytics,” said Patrick Blattner, Co-Founder and Chief Product Officer of The Indoor Lab . “Last week at the 3rd Annual Qualcomm Smart Cities Accelerate Event, we were proud to showcase our solution and its wide variety of applications to the global Qualcomm Smart Cities Accelerator Program ecosystem.”
"We are pleased to welcome Cepton as a member of our cutting-edge Qualcomm Smart Cities Accelerator Program. We look forward to working together to bring cutting-edge smart lidar solutions and applications to a variety of urban environments and collaborating to offer Smart Venues as a Service through the Qualcomm® IoT Services Suite," said Sanjeet Pandit, Senior Director, Business Development, and Global Head of Smart Cities, Qualcomm Technologies, Inc.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm IoT Services Suite is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom